Compare CCSI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | PROK |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.6M | 416.6M |
| IPO Year | 2022 | 2021 |
| Metric | CCSI | PROK |
|---|---|---|
| Price | $37.46 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.50 | $7.40 |
| AVG Volume (30 Days) | 141.0K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $349,696,000.00 | $893,000.00 |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | $29.51 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $19.42 | $1.53 |
| 52 Week High | $41.40 | $4.05 |
| Indicator | CCSI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 39.68 |
| Support Level | $35.92 | N/A |
| Resistance Level | $41.40 | $2.59 |
| Average True Range (ATR) | 1.82 | 0.17 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 42.65 | 7.86 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.